文献速递脑血管病

区域卒中网络换用替奈普酶溶栓的真实世界结局

Switching to Tenecteplase for Stroke Thrombolysis: Real-World Experience and Outcomes in a Regional Stroke Network.
PubMed 文献 · Stroke · 2021-08-31

为评估从阿替普酶换用替奈普酶的区域性实施效果,本研究采用混合方法,在新西兰国家卒中登记数据中比较555例阿替普酶与283例替奈普酶患者的结局。替奈普酶组功能预后更优且门-针时间更短,症状性颅内出血和7天死亡无显著差异。

要点

  • 替奈普酶组功能预后更优(调整OR 1.60,95%CI 1.15–2.22)。
  • 替奈普酶组门-针时间中位数更短(53 vs 61分钟,P=0.0002)。
  • 症状性颅内出血与7天死亡在两组间无显著差异。

核心结论

  • 区域范围内从阿替普酶换用替奈普酶溶栓成功实施,证据显示获益且无损害证据。

研究设计与样本

  • 混合方法研究,包括利益相关者参与、实施前后调查,并基于新西兰国家卒中登记数据回归分析调整年龄、性别、NIHSS评分、病前mRS评分和取栓。
  • 2018年1月至2021年2月,555例患者接受阿替普酶治疗,283例接受替奈普酶治疗。

主要发现

  • 替奈普酶组功能预后更优:mRS位移分析调整OR 1.60(95%CI 1.15–2.22),mRS 0–2二分分析调整OR 2.17(95%CI 1.31–3.59)。
  • 替奈普酶组门-针时间中位数(IQR)为53(38–73.5)分钟,阿替普酶组为61(45–85)分钟,P=0.0002。
  • 症状性颅内出血率替奈普酶1.8% vs 阿替普酶3.4%,调整OR 0.46(95%CI 0.13–1.64)。
  • 7天死亡率替奈普酶7.5% vs 阿替普酶11.8%,调整OR 0.46(95%CI 0.21–0.99)。
  • 42例转运患者的针-腹股沟时间中位数(IQR)替奈普酶155(113–248)分钟 vs 阿替普酶200(158–266)分钟,P=0.27。

临床怎么用

  • 在利益相关者支持下,可区域化实施从阿替普酶到替奈普酶的溶栓转换,并关注门-针时间改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Due to practical advantages, increasing trial safety data, recent Australian Guideline endorsement and local population needs we switched to tenecteplase for stroke thrombolysis from alteplase. We describe our change process and real-world outcome data. METHODS: Mixed-methods including stakeholder engagement, preimplementation and postimplementation surveys, and assessment of patient treatment rates, metrics, and clinical outcomes preimplementation and postimplementation adjusting regression analyses for age, sex, National Institutes of Health Stroke Scale, premorbid modified Rankin Scale score, and thrombectomy using New Zealand National Stroke Registry data. RESULTS: Preswitch consultation involved stroke and emergency clinicians, pharmacists, national regulatory bodies, and hospital legal teams. All survey responders (90% response rate) supported the proposed change and remained satisfied 12 months postimplementation. Between January 2018 and February 2021, we treated 555 patients with alteplase and 283 with tenecteplase. Patients treated with tenecteplase had greater odds of a favorable modified Rankin Scale using both shift (adjusted odds ratio, 1.60 [95% CI, 1.15–2.22]) and dichotomous analyses (modified Rankin Scale score, 0–2; adjusted odds ratio, 2.17 [95% CI, 1.31–3.59]) and shorter median (interquartile range) door-to-needle time (median, 53 [38–73.5] versus 61 minutes [45–85], P=0.0002). Symptomatic intracranial hemorrhage rates (tenecteplase 1.8% versus 3.4%; adjusted odds ratio, 0.46 [95% CI, 0.13–1.64]), death by day 7 (tenecteplase 7.5% versus 11.8%; adjusted odds ratio, 0.46 [95% CI, 0.21–0.99]), and median (interquartile range) needle to groin time for the 42 transferred regional patients (tenecteplase 155 [113–248] versus 200 [158–266]; P=0.27) did not significantly differ. CONCLUSIONS: Following stakeholder endorsement, a region-wide switch from alteplase to tenecteplase was successfully implemented. We found evidence of benefit and no evidence of harm.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mahawish K, Gommans J, Kleinig T, et al. Switching to Tenecteplase for Stroke Thrombolysis: Real-World Experience and Outcomes in a Regional Stroke Network. Stroke. 2021. PMID: 34465202. doi:10.1161/STROKEAHA.121.035931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。